References

  1. Aghamiri S et al. Antibiotic Resistance Patterns and a Survey of Metallo-beta-Lactamase Genes Including bla-IMP and bla-VIM Types in Acinetobacter baumannii Isolated from Hospital Patients in Tehran. Chemotherapy. 2016; 61(5): 275-280. PubMed | Google Scholar

  2. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med. 2003; 24(1): 69-78. PubMed | Google Scholar

  3. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011; 37(2): 102-9. PubMed | Google Scholar

  4. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006; 43(3): 389; author reply 389-90. PubMed | Google Scholar

  5. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006; 12(9): 826-36. PubMed | Google Scholar

  6. Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen. J Pathog. 2016; 2016: 7318075. PubMed | Google Scholar

  7. Moradi JF, Hashemi B, Bahador A. Antibiotic Resistance of Acinetobacter baumannii in Iran: A Systemic Review of the Published Literature. Osong Public Health Res Perspect. 2015; 6(2): 79-86. PubMed | Google Scholar

  8. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J Antimicrob Chemother. 2006; 57(3): 373-83. PubMed | Google Scholar

  9. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother. 2007; 60(3): 470-82. PubMed | Google Scholar

  10. Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014; 27(2): p. 241-63. PubMed | Google Scholar

  11. Lee K et al. Multidrug-resistant Acinetobacter spp: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011; 52(6): 879-91. PubMed | Google Scholar

  12. Opazo A et al. OXA-type carbapenemases in Acinetobacter baumannii in South America. J Infect Dev Ctries. 2012; 6(4): 311-6. PubMed | Google Scholar

  13. Zahedi Bialvaei A et al. Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. Iran J Microbiol. 2015; 7(5): 226-46. PubMed | Google Scholar

  14. Yang HY et al. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. Yonsei Med J. 2009; 50(6): 764-70. PubMed | Google Scholar

  15. Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol. 2002; 3(2): 117-27. PubMed | Google Scholar

  16. Hammami S et al. Carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in Tunisia. Tunis Med. 2011; 89(7): 638-43. PubMed | Google Scholar

  17. Tenover FC et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33(9): 2233-9. PubMed | Google Scholar

  18. Bergogne-Berezin ETK. Acinetobacter spp as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996; 148-165. PubMed | Google Scholar

  19. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med. 2003; 24: 69-78. PubMed | Google Scholar

  20. Gootz TD MA. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther. 2008; 6: 309-325. PubMed | Google Scholar

  21. Abbo A N-VS, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005; 22-29. PubMed | Google Scholar

  22. Kim YJ et al. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci. 2012; 27(5): p. 471-5. PubMed | Google Scholar

  23. Yang YS et al. Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients? BMC Infect Dis. 2013; 13: 142. Google Scholar

  24. Zarrilli R et al. Clonal spread and patient risk factors for acquisition of extensively drug-resistant Acinetobacter baumannii in a neonatal intensive care unit in Italy. J Hosp Infect. 2012; 82(4): 260-5. PubMed | Google Scholar

  25. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002; 8(6): 321-331. PubMed | Google Scholar

  26. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012; 39(2): 105-14. PubMed | Google Scholar

  27. Turton JF et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006; 258(1): 72-7. PubMed | Google Scholar

  28. Héritier CL, Poirel and Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii.Clin Microbiol Infect. 2006; 12(2): 123-30. PubMed | Google Scholar

  29. Carvalho KR et al. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents. 2009; 34(1): 25-8. PubMed | Google Scholar

  30. Donald HM et al. Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother. 2000; 44(1): 196-9. PubMed | Google Scholar

  31. Corvec S et al. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(4): 1530-3. PubMed | Google Scholar

  32. Wang H et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp from Chinese hospitals. Antimicrob Agents Chemother. 2007; 51(11): 4022-8. PubMed | Google Scholar

  33. Poirel L et al. Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp. Antimicrob Agents Chemother. 2008; 52(4): 1252-6. PubMed | Google Scholar

  34. Romanelli RM et al. Outbreak of resistant Acinetobacter baumannii- measures and proposal for prevention and control. Braz J Infect Dis. 2009; 13(5): 341-7. PubMed | Google Scholar

  35. Bush K. New beta-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001; 32(7): 1085-9. PubMed | Google Scholar

  36. Boulanger A et al. NDM-1-producing Acinetobacter baumannii from Algeria. Antimicrob Agents Chemother. 2012; 56(4): 2214-5. PubMed | Google Scholar

  37. Amudhan MS et al. BlaIMP and blaVIM mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India. J Infect Dev Ctries. 2012; 6(11): 757-62. PubMed | Google Scholar

  38. Hussenet C et al. Multidrug-resistant Acinetobacter baumannii infections in three returning travelers evacuated from Algeria, Thailand, and Turkey after hospitalization in local intensive care units. J Travel Med. 2011; 18(5): 358-60. PubMed | Google Scholar

  39. Gehrlein M et al. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy. 1991; 37(6): 405-12. PubMed | Google Scholar

  40. Mendes RE et al. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother. 2009; 63(1): 55-9. PubMed | Google Scholar